ChromaDex Offers a Comprehensive Line of Taxane Standards

IRVINE, Calif., July 1, 2011 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), a world leader in phytochemical reference standards and contract research, announces the addition of the Cedarburg Hauser Pharmaceuticals line of taxane and natural products standards to its reference standard offering. Laboratories doing taxane analysis will now have a one-stop shop for all of their taxane standards requirements.

"ChromaDex is at the forefront of providing the most complete library of phytochemical reference standards. The inclusion of the Cedarburg Hauser taxane standards to our portfolio helps round out our product offering in this very important area," stated Frank Jaksch, CEO and co-founder of ChromaDex. "We are committed to serving the natural products industry with the materials and technologies needed to ensure fast accurate test results."

About ChromaDex

ChromaDex is a world leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable, "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools, products, and services to meet the regulatory, quality, efficacy and safety standards for their products. To learn more, visit www.ChromaDex.com.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
[email protected]

ChromaDex Contact
Laura Carney
Executive Assistant to the CEO, President, and CFO
10005 Muirlands Blvd, Suite G, Irvine, CA 92618
949-419-0288
[email protected]

Media Inquiries:
Carolyn Hawley
Canale Communications
619-849-5375
[email protected]

SOURCE ChromaDex Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED